trial

Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward

NCTId NCT00418873
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 39 (actual)
Sponsored by Astellas Pharma Global Development, Inc.
Primary completion 2009-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
39 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2007-03
Primary completion
2009-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
ZotepineRisperidone

Sponsors

Astellas Pharma Global Development, Inc.Lead Sponsor
Astellas Pharma Global Development, Inc.Collaborator

Investigators

1
Chang-Jer TsaiPrincipal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
39
Phase
PHASE4
Primary Completion Date
2009-12
Status
TERMINATED
relationships
The graph out of here
drug
Zotepine
drug
Risperidone
drug
lead_sponsor
Astellas Pharma Global Development, Inc.
company
collaborator
Astellas Pharma Global Development, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Chang-Jer Tsai
person